NoName_3327 → 6-[4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid(1H-indazol-4-yl)-amide

HRID 74695

反応式

HRID 74695 の反応式
[CH3:1][O:2][C:3]1[CH:29]=[CH:28][C:6]2[NH:7][C:8](=[O:27])[N:9]([CH:12]3[CH2:17][CH2:16][N:15]([C:18]4[CH:23]=[C:22]([C:24]([OH:26])=O)C=C[N:19]=4)[CH2:14][CH2:13]3)[CH2:10][CH2:11][C:5]=2[CH:4]=1.[NH2:30][C:31]1[CH:39]=[CH:38][CH:37]=[C:36]2[C:32]=1[CH:33]=[N:34][NH:35]2.[CH3:40][N:41](C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>CN(C=O)C>[NH:35]1[C:36]2[C:32](=[C:31]([NH:30][C:24]([C:22]3[CH:23]=[C:18]([N:15]4[CH2:16][CH2:17][CH:12]([N:9]5[CH2:10][CH2:11][C:5]6[CH:4]=[C:3]([O:2][CH3:1])[CH:29]=[CH:28][C:6]=6[NH:7][C:8]5=[O:27])[CH2:13][CH2:14]4)[N:19]=[CH:40][N:41]=3)=[O:26])[CH:39]=[CH:38][CH:37]=2)[CH:33]=[N:34]1

参加物

5

反応物 3

HCID 413085NoName_3327HCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 583864334-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4'-carboxylic acid

生成物 1

HCID 426132236-[4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid(1H-indazol-4-yl)-amide

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

100 mg (0.25 mmol) 4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-carboxylic acid and 34 mg (0.25 mmol) 4-amino-indazole in 74 mμL (0.53 mmol) TEA and 1.5 mL DMF were combined with 89 mg (0.28 mmol) TBTU and the mixture was stirred overnight at RT. Then the reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and freeze-dried.

後処理

  1. customThen the reaction mixture was purified by preparative HPLC-MS
  2. customfreeze-dried

出典と根拠

ORDレコード
ord-2832dc2c146b469cb93d3bc6b833b7f1
出典データセット
uspto-grants-2014_09
特許番号
US08829006B2

関連ノート

読み込み中…